Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
36 hedge funds and large institutions have $16.3M invested in Vyant Bio, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
95% more capital invested
Capital invested by funds: $8.33M → $16.3M (+$7.95M)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
24% more funds holding
Funds holding: 29 → 36 (+7)
47% less call options, than puts
Call options by funds: $31K | Put options by funds: $59K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
+$1.4M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.34M |
| 3 |
Renaissance Technologies
New York
|
+$599K |
| 4 |
Morgan Stanley
New York
|
+$173K |
| 5 |
Millennium Management
New York
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sterneck Capital Management
Kansas City,
Missouri
|
-$381K |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$317K |
| 3 |
QGM
Quality Growth Management
Rancho Santa Fe,
California
|
-$115K |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$52.9K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$26.4K |
VYNT Hedge Fund Activity: Q2 2015 in Review
36 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2015, worth a combined $16.3M — up 95% from $8.33M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VYNT positions and 2 closed out — a net gain of 7 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Allianz Asset Management, opening a new position worth an estimated $1.4M. The largest seller was Sterneck Capital Management, cutting an estimated $381K.
- 36 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2015, up from 29 in Q1 2015.
- Funds reported $16.3M of Vyant Bio, Inc. Common Stock stock for Q2 2015, up 95% quarter-over-quarter.
- 9 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2015 and 2 closed out, a net change of +7 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2015 was Allianz Asset Management, an estimated $1.4M added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2015 was Sterneck Capital Management, an estimated $381K sold.
Based on aggregated 13F filings for Q2 2015.